Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

taVNS and Rehabilitation After Grasp Reconstruction in Tetraplegia: A Randomized Feasibility Study (TeGRASP-VNS)

19 de novembro de 2026 atualizado por: Lina Bunketorp Käll, Sahlgrenska University Hospital

Effects of Transcutaneous Vagus Nerve Stimulation Combined With Rehabilitation on Clinical Outcomes Following Surgical Reconstruction of Grasp Function in Tetraplegia: A Randomized, Triple-Blind, Sham-Controlled Feasibility Study

The goal of this clinical trial is to learn whether transcutaneous auricular vagus nerve stimulation (taVNS) is feasible, safe and tolerable when combined with standard rehabilitation after surgery to restore grasp in adults with tetraplegia caused by spinal cord injury. taVNS delivers gentle electrical stimulation through an electrode placed on the outer ear.

The main questions it aims to answer are:

  • Can participants follow the treatment schedule and complete the study assessments?
  • Is the treatment well tolerated, and what side effects or medical problems occur?
  • Are there preliminary differences in grasp function, tendon movement and daily activities between participants receiving active treatment and those receiving sham treatment?
  • Does active treatment affect blood markers of inflammation and scar tissue formation? Researchers will compare active taVNS with sham treatment delivered using an identical device and a specially designed electrode that provides subtle sensory feedback without electrical stimulation. Both groups will receive the same standard postoperative rehabilitation. Approximately 40 adults undergoing surgical grasp reconstruction at the Center for Advanced Reconstruction of Extremities (CARE), Sahlgrenska University Hospital/Mölndal, Sweden, will be randomly assigned to the two groups in equal numbers. Participants, treating therapists and outcome assessors will not know which treatment participants receive.

Participants will:

  • Use the assigned device with an electrode on the left outer ear for 60 minutes daily, starting during the week of surgery and continuing for three months.
  • Receive training, together with a caregiver where needed, to use the device at home.
  • Return for a five-day inpatient rehabilitation stay three weeks after surgery, during which treatment will be supervised.
  • Complete assessments before surgery and at three weeks, 12 weeks, six months and 12 months after surgery.
  • Complete tests of grasp function, grip and pinch strength, hand opening and movement, together with questionnaires about daily activities, independence, bowel function, mood and quality of life.
  • Undergo ultrasound examinations to assess tendon movement and scar tissue around the tendons.
  • Provide blood samples before and at several time points after surgery to investigate inflammation and tissue healing.
  • Record each treatment session in a diary and report side effects or difficulties using the device.

Approximately 10-15 participants will also be invited to an interview about their experiences of treatment and rehabilitation around three months after surgery.

This feasibility study will help researchers plan a larger trial to determine whether adding taVNS to rehabilitation improves recovery after surgical grasp reconstruction.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Cervical spinal cord injury (SCI) frequently results in tetraplegia and severe impairment of hand function. Reconstructive surgery using tendon and muscle transfers can restore active grasp function and improve independence. However, postoperative scar formation and peritendinous adhesions may restrict tendon gliding and compromise functional recovery.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique with potential anti-inflammatory effects mediated through the cholinergic anti-inflammatory pathway. These effects may influence postoperative inflammation and tissue remodeling. However, the feasibility and potential clinical benefits of taVNS following reconstructive hand surgery in individuals with tetraplegia have not previously been systematically investigated.

This single-center, randomized, triple-blind, sham-controlled feasibility trial will enroll 40 adults with tetraplegia undergoing surgical reconstruction of grasp function at Sahlgrenska University Hospital, Sweden. Participants will be consecutively recruited and randomly allocated in a 1:1 ratio to active taVNS or sham stimulation, both combined with standard postoperative rehabilitation. Randomization will be stratified according to the International Classification for Surgery of the Hand in Tetraplegia (ICSHT).

Stimulation will be initiated during the week of surgery and administered for 60 minutes daily over a three-month period, primarily in the home setting. Active stimulation will be delivered to the left tragus using a Nurosym device at 25 Hz and a pulse width of 250 μs. The sham group will use an identical device with a sham electrode that does not deliver electrical stimulation.

The primary objective is to evaluate the feasibility, safety, tolerability, and acceptability of integrating taVNS into postoperative rehabilitation. Feasibility will be assessed through recruitment, adherence, retention, and treatment-related safety outcomes.

Preliminary clinical effects will be explored through assessments of grasp function, muscle strength, range of motion, tendon gliding, independence, activity performance, and quality of life. Blood samples collected during the early postoperative period will be used to investigate inflammatory and tissue-remodeling responses. A qualitative substudy will explore participants' experiences of using taVNS during postoperative rehabilitation.

Clinical assessments will be conducted before surgery and at approximately 3 weeks, 3 months, 6 months, and 12 months postoperatively. Findings will inform the design and implementation of a future definitive randomized controlled trial.

Tipo de estudo

Intervencional

Inscrição (Estimado)

40

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Adults (≥18 years) with tetraplegia due to SCI
  • Planned reconstructive surgery of the upper limb to restore grip function
  • Medically stable and considered suitable for surgery and postoperative rehabilitation
  • Ability to understand the study information and provide informed consent
  • Ability to participate in postoperative rehabilitation and follow-ups according to the study protocol

Exclusion Criteria:

  • Implanted pacemaker, ICD, neurostimulator, or previous surgery on the vagus nerve

    • Contraindication to electrical stimulation or electrode placement at the tragus
    • Clinically significant cardiac arrhythmia, symptomatic bradycardia, or myocardial infarction within the past five years
    • Severe autonomic instability (e.g., recurrent autonomic dysreflexia requiring acute treatment, syncope due to orthostatic hypotension, or unstable blood pressure)
    • Trigeminal neuralgia within the past year
    • Active systemic autoimmune or inflammatory disease or ongoing immunosuppressive therapy
    • Progressive neuromuscular disease affecting upper limb function
    • Severe psychiatric illness or substance use disorder affecting study participation
    • Any other medical condition that, in the investigator's judgment, may affect the subject's ability to participate safely in the study or interfere with the interpretation of the study results.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Active vagus nerve stimulation paired with standard postoperative rehabilitation

Stimulation will be initiated during the week of surgery and administered for 60 minutes daily over a three-month period, primarily in the home setting. Active stimulation will be delivered to the left tragus using a Nurosym device at 25 Hz and a pulse width of 250 μs.

Active taVNS will be delivered using the Nurosym device (Parasym Health Ltd., UK), with the electrode positioned on the left tragus. Stimulation will be administered at 25 Hz and 250 μs, with intensity individually adjusted to a comfortable sensory level and then reduced by one increment. Treatment will be administered for 60 minutes daily over three months, alongside standard postoperative rehabilitation.

Outros nomes:
  • Auricular Vagus Nerve Stimulation (aVNS)
  • Transcutaneous Vagus Nerve Stimulation (tVNS)
Comparador Ativo: Placebo vagus nerve stimulation paired with standard postoperative rehabilitation

The sham group will use an identical device with a sham electrode that does not deliver electrical stimulation.

Sham taVNS will be delivered using an identical Nurosym device equipped with a sham electrode positioned on the left tragus, providing subtle sensory feedback without electrical stimulation. Treatment will follow the same schedule as active taVNS (60 minutes daily for three months), alongside standard postoperative rehabilitation.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in grip function as assessed by Grasp and Release Test (GRT)
Prazo: From enrollment to the last follow-up at 12 months

The primary clinical outcome measure is grip function evaluated using the Grasp and Release Test (GRT). This test assesses the ability to pick up, move, and release six objects of varying size, weight, and surface texture using either a power grasp (cylindrical grip) or a pinch grasp (key grip). The GRT was developed to evaluate grip function following reconstructive surgery in individuals with tetraplegia. The instrument has demonstrated good test-retest reliability and is capable of detecting changes in hand function following tendon transfer procedures.

From enrollment to the last follow-up at 12 months
Recruitment rate
Prazo: From enrollment to the last follow-up at 12 months.

Recruitment rate will be evaluated by recording the number of screened, included, and randomized participants, as well as the proportion of participants who complete the study protocol. Reasons for non-inclusion and declined participation will be documented whenever possible.

From enrollment to the last follow-up at 12 months.
Adherence to the intervention
Prazo: From the first treatment session to the end of treatment at 12 weeks.

Adherence to the intervention will be evaluated by having participants, with support from assistants or relatives if needed, document all treatment sessions in a treatment diary.

From the first treatment session to the end of treatment at 12 weeks.
Dropouts and study discontinuations
Prazo: From enrollment to the last follow-up at 12 months.

Dropouts and study discontinuations will be systematically recorded, and reasons for withdrawal will be documented. The intention-to-treat principle will be applied in the data analysis.

From enrollment to the last follow-up at 12 months.
The quality of blinding
Prazo: From the first treatment session to the end of treatment at 12 weeks.

The quality of blinding will be evaluated by asking participants, after assessing the primary outcome measure, about their perceived group allocation and the degree of certainty regarding this assumption. Participants will select one of five predefined response options: certain they received taVNS, believed they received taVNS, certain they received sham stimulation, believed they received sham stimulation, or uncertain of their group allocation.

From the first treatment session to the end of treatment at 12 weeks.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Prazo: From the start of treatmetnt to the last follow-up at 12 months.

Safety and Tolerability will be evaluated through documentation of treatment-related discomfort, discontinuation of the intervention, and the occurrence of adverse events (AE) and serious adverse events (SAE).

From the start of treatmetnt to the last follow-up at 12 months.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in grip strength as assessed by JAMAR hydraulic hand dynamometer
Prazo: From enrollment to the last follow-up at 12 months

Grip strength will be measured using a JAMAR hydraulic hand dynamometer, which has demonstrated good validity and reliability. The participant is instructed to sit with the elbow flexed at 90 degrees, then grips as forcefully as possible using a cylindrical grip for 3-5 seconds. Three measurements will be performed, and the highest value will be used for analysis

From enrollment to the last follow-up at 12 months
Change from baseline in pinch grep strenght as assessed by Pinch Gauge
Prazo: From enrollment to the last follow-up at 12 months

Pinch grip strength (key pinch) will be measured using a Pinch Gauge. Measurement of pinch strength is a reliable tool in many musculoskeletal, systemic, and neurological conditions, and has proven useful in individuals with tetraplegia. Participants sit with the arm alongside the body and the elbow flexed at 90 degrees. The maximum value of three attempts will be used for analysis.

From enrollment to the last follow-up at 12 months
Change in the ability to grasp and release objects as assessed by he Cylinder Test
Prazo: From enrollment to the last follow-up at 12 months

The Cylinder Test assesses the patient's ability to grasp and release cylinders of varying diameters ranging from 20 to 150 mm. Preliminary evaluation supports the face validity, manual clarity, feasibility, and perceived clinical relevance of the CyT for assessing functional hand opening in neurological upper limb rehabilitation

From enrollment to the last follow-up at 12 months
Change from baseline in active and passive range of motion as assessed by a goniometer
Prazo: From enrollment to the last follow-up at 12 months

The universal goniometer has shown good to excellent reliability in previous studies. To ensure high measurement reliability, all measurements will be performed by the same therapist, using a standardized method and the same measurement instrument.

From enrollment to the last follow-up at 12 months
Change from baseline in active and passive range of finger motion (tendon gliding) as assessed by Total Active Motion (TAM) and Total Passive Motion (TPM)
Prazo: From enrollment to the last follow-up at 12 months

To obtain a functional measure of tendon gliding, Total Active Motion (TAM) and Total Passive Motion (TPM) will be used. TAM is calculated according to the standardized method developed by the American Society for Surgery of the Hand (ASSH). TAM is defined as the sum of active motion in the metacarpophalangeal (≈85°), proximal interphalangeal (≈110°), and distal interphalangeal joints (≈65°) minus any extension deficit in the same joints. To express active motion as a percentage, the measured TAM value is divided by 260 and multiplied by 100. The same principle is applied when calculating TPM. Results are classified as follows: 100% = normal; 75-99% = good; 50-74% = fair; <50% = poor. A large TPM combined with a low TAM strongly suggests tendon adhesions and impaired tendon gliding. Similar values for TAM and TPM indicate joint stiffness rather than adhesions. The difference between TAM and TPM is therefore used clinically to identify tendon adhesions.

From enrollment to the last follow-up at 12 months
Change from baseline in activity performance as assessed by the Canadian Occupational Performance Measure (COPM)
Prazo: From enrollment to the last follow-up at 12 months

COPM is an individualized and client-centered instrument designed to detect changes over time in an individual's self-perceived performance in daily activities. COPM has demonstrated good test-retest reliability and validity across multiple populations, treatment settings, and countries, and is sensitive to change in individuals with SCI.

From enrollment to the last follow-up at 12 months
Change from baseline in activity performance as assessed by the Tetraplegic Upper Limb Activity Questionnaire (TUAQ)
Prazo: From enrollment to the last follow-up at 12 months

TUAQ assesses performance and satisfaction in individuals with tetraplegia. Each scale includes the same ten questions with a five-point response scale. Scores are summed into a raw score for each scale and then converted into interval scales using a conversion table. TUAQ is intended for both clinical assessment and as an outcome measure following upper limb interventions in tetraplegia and has demonstrated good internal validity and reliability.

From enrollment to the last follow-up at 12 months
Dynamic ultrasound and differential motion testing (tendon excursion)
Prazo: From enrollment to the last follow-up at 12 months

Adhesion formation and tendon gliding will be evaluated using dynamic ultrasound and differential motion testing (tendon excursion) three months postoperatively. Previous studies have shown ultrasound to be useful for identifying adhesions. The examination is performed using a high-frequency probe in longitudinal and transverse views while the patient performs finger movements. The assessment evaluates how freely and smoothly the tendon glides, any movement delay, and signs of adhesions such as restricted tendon movement or surrounding tissue moving together with the tendon.

From enrollment to the last follow-up at 12 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change from baseline in health-related quality of life as assessed by EuroQol-5D (EQ-5D)
Prazo: From enrollment to the last follow-up at 12 months

Respondents rate their health across five specific dimensions, with each dimension evaluated on a 5-level severity scale (from 1 = no problems to 5 = extreme problems / unable to perform):

Mobility: Walking and moving about. Self-Care: Washing or dressing oneself. Usual Activities: Work, study, housework, family, or leisure activities. Pain / Discomfort: Physical aches or suffering. Anxiety / Depression: Emotional state, feeling worried, sad, or unhappy.

Combining the score (1 to 5) from each of the five dimensions creates a unique 5-digit health state profile.

The EQ VAS (Visual Analogue Scale) is a vertical, thermometer-style scale (ranging from 0 to 100) where patients mark their overall health today. 0 represents "the worst health you can imagine," and 100 represents "the best health you can imagine".

From enrollment to the last follow-up at 12 months
Change from baseline in mental health as assesseb by Patient Health Questionnaire (PHQ-9)
Prazo: From enrollment to the last follow-up at 12 months

PHQ-9 is a validated short self-report scale used for screening major depression and assessing the current level of depressive symptoms. Patients report how often they have experienced nine different problems over the past two weeks, such as feeling down or hopeless, sleep disturbances, or difficulty concentrating. A tenth item assesses functional impairment, indicating how these symptoms affect work, household responsibilities, and social interactions. As a severity measure, the PHQ-9 score can range from 0 to 27, since each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day).

From enrollment to the last follow-up at 12 months
Change from baseline in bowel function as assessed by the Neurogenic Bowel Dysfunction (NBD) score
Prazo: From enrollment to the last follow-up at 12 months

The Neurogenic Bowel Dysfunction (NBD) Score is a 10-item, symptom-based questionnaire designed to evaluate bowel management and symptom severity-originally developed for patients with spinal cord injuries. The validated NBD questionnaire consists of 10 questions covering bowel emptying time, constipation, fecal incontinence, uncontrollable gas, and perianal skin problems. The total score indicates the severity of bowel dysfunction.

  • Total Score Range: 0 to 47 points (each response is weighted based on its impact on quality of life).
  • 0-6 points: Very minor bowel dysfunction
  • 7-9 points: Minor bowel dysfunction
  • 10-13 points: Moderate bowel dysfunction
  • 14+ points: Severe bowel dysfunction
From enrollment to the last follow-up at 12 months
Change in functional ability and degree of independence as assessed by Spinal Cord Independence Measure IV
Prazo: From enrollment to the last follow-up at 12 months

SCIM IV is a comprehensive clinical assessment tool designed to measure independence in individuals with SCI when performing basic activities of daily living (ADL). SCIM IV evaluates 19 items across three main domains, yielding a total score from 0 to 100:

  • Self-Care (Items 1-4, Score: 0-20): Evaluates daily activities such as feeding, bathing, and dressing.
  • Respiration and Sphincter Management (Items 5-8, Score: 0-40): Evaluates respiration, bladder management, bowel management, and use of the toilet.
  • Mobility (Items 9-14 / 9 items total, Score: 0-40): Divided into two sub-areas:
  • Room and toilet mobility: Bed mobility, pressure sore prevention actions, and bed-to-wheelchair / wheelchair-to-toilet-tub transfers.
  • Indoors and outdoors mobility: Short, moderate, and long-distance mobility, stair management, and car-to-wheelchair transfers
From enrollment to the last follow-up at 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2031

Conclusão do estudo (Estimado)

1 de dezembro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

9 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de novembro de 2026

Primeira postagem (Real)

20 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever